ArticleCombinatorial chemistry & high throughput screening2026
Candidate Gene Identification: SOX11 Downregulation and IL-7 Upregulation Correlate with the Pro-Proliferative Effect of Mesenchymal Stem Cell-Derived Exosomes on Schwann Cells.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
INTRODUCTION/
backgroundSchwann cell (SC) proliferation is crucial for repairing peripheral nerve injuries (PNIs), and mesenchymal stem cell-derived exosomes (MSCs-Exos) show promise in treating PNIs.
methodsThe characterization process was performed by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. SCs were co-cultured with menstrual blood-derived MenSCs-Exos to assess their proliferation through CCK-8 assay and flow cytometry. RNA-Seq was utilized to identify differentially expressed genes (DEGs) linked to SC proliferation. DEGs were subjected to GSEA and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Finally, the overexpression of SOX11 and the knockout of IL-7 were carried out, and the functions of SOX11 and IL-7 were verified using the CCK8 assay and flow cytometry.
resultsMenSCs exhibited osteogenic and adipogenic differentiation potential, and MenSCs-Exos demonstrated typical exosomal characteristics. These exosomes were efficiently internalized by SCs, promoting their proliferation and cell cycle progression. RNA-Seq identified 113 differentially expressed genes (DEGs) (60 upregulated and 53 downregulated) in Schwann cells (SCs) treated with MenSCs-derived exosomes (MenSCs-Exos) relative to the untreated control group. After excluding DEGs that were also altered in the MenSCs-conditioned medium (CM) group, 18 unique DEGs specific to the MenSCs-Exos treatment were further identified. qRT-PCR and Western blot showed notably upregulated IL22RA2 and IL-7 expression and a reduction in SOX11 level. Further knockout and overexpression experiments confirmed that downregulation of SOX11 and the upregulation of IL-7 might be related to the proliferative-promoting effect of MSCs-Exos on Schwann cells. DISCUSSION: MenSCs-Exos can be efficiently internalized by SCs and significantly promote their proliferation and cell cycle progression by upregulating IL-7 and downregulating SOX11. This suggests that MenSCs-Exos may enhance SCs' proliferative capacity and repair ability through this molecular mechanism.
conclusionThis study confirms the therapeutic potential of MenSCs-Exos in promoting neural regeneration, identifies key genes and pathways regulating Schwann cell proliferation, thereby providing novel molecular targets and experimental evidence for further elucidation of exosome-mediated repair mechanisms.
Indexed as
Identifiers
42059236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.